Urolithin A, Mitophagy, and Healthy Aging: What Human Research Reveals

Urolithin A has become one of the more extensively investigated nutritional compounds in mitochondrial aging research. Its ability to influence mitochondrial quality control first attracted attention in laboratory studies, followed by human investigations involving muscle function, endurance, and metabolic biomarkers. More recent research has extended those questions into immune-cell metabolism, exercise recovery, brain circulation, and cardiovascular biology.

What makes this research worth following is the convergence of findings from several directions. In middle-aged and older adults, investigators have observed changes in selected muscle measures and mitochondrial-related proteins. More recently, they have begun examining how immune cells organize their energy metabolism and how cerebral circulation responds to cognitive demand. These observations are not interchangeable measures of health, but together they suggest that urolithin A is influencing biological processes relevant to how tissues adapt and maintain function with age.

What Is Urolithin A?

Urolithin A is a postbiotic metabolite formed through the interaction between dietary plant compounds and intestinal microorganisms. Pomegranates, walnuts, raspberries, and strawberries contain ellagitannins or ellagic acid that can be metabolized into urolithins by certain gut bacteria.

The capacity to produce urolithin A varies considerably among individuals. Differences in gut microbial communities mean that consuming the same quantity of a food does not necessarily result in comparable exposure to the compound. Supplemental urolithin A bypasses this variable microbial conversion and delivers a standardized amount that can be evaluated in clinical trials.

Its scientific significance arises primarily from its interaction with mitochondrial quality-control pathways. Mitochondria produce much of the energy used by our cells, but they also participate in nutrient sensing, inflammatory signaling, cellular stress responses, and the regulation of metabolism. Their function depends on the ongoing removal, repair, and replacement of mitochondrial components.

Why Mitophagy Matters in Healthy Aging

Mitophagy is a specialized form of autophagy through which cells identify and recycle mitochondria that are damaged or no longer functioning efficiently. Mitochondrial quality control also depends on the creation of new mitochondria, the exchange of mitochondrial components, and the ability of mitochondrial networks to adapt to changing energy requirements.

With advancing age, these processes may become less efficient. The consequences can extend beyond reduced cellular energy production because mitochondrial dysfunction can influence oxidative stress, inflammation, nutrient metabolism, and communication between cells.

Researchers have therefore become interested in whether improving mitochondrial quality control can influence the development of age-related functional decline. Urolithin A has emerged as an especially interesting candidate because experimental studies have repeatedly identified effects on pathways associated with mitophagy, and human research has begun to demonstrate related metabolic changes.

These processes also help explain why mitochondrial research is increasingly connected with immune aging, cardiometabolic health, and physical resilience. Mitochondria are active participants in cellular regulation throughout the body, and their quality-control systems are relevant to multiple organ systems.

What Human Muscle Studies Have Found

The first human studies of urolithin A established that oral supplementation could produce measurable systemic exposure and changes in molecular pathways associated with mitochondrial biology. Subsequent randomized trials examined whether those biological effects translated into improved muscle performance.

Middle-Aged Adults

A randomized trial published in Cell Reports Medicine in 2022 enrolled 88 untrained, overweight middle-aged adults who received placebo, 500 mg of urolithin A daily, or 1,000 mg daily for four months.

Researchers reported improvements in selected measurements of hamstring strength and changes in biomarkers related to mitochondrial health and inflammation. These findings attracted considerable attention because they suggested that an intervention targeting mitochondrial biology might influence aspects of physical function in people who were not participating in a structured training program.

The reported improvement of approximately 12% in muscle strength refers to selected hamstring measurements rather than a uniform increase across all muscle groups. Hand-grip strength and lean body mass did not significantly improve, and the trial's primary exercise-performance endpoint was not significantly better than placebo.

What the Mitopure® “39% Mitochondrial Renewal” Finding Means

Timeline has highlighted a 39% improvement in “mitochondrial renewal” after 16 weeks of 500 mg Mitopure® compared with placebo. That phrasing describes a biological signal from the trial rather than a direct measurement showing that 39% of damaged mitochondria were physically removed and replaced. In the published muscle-biopsy analyses, investigators identified changes in proteins involved in the PINK1/Parkin pathway, including phosphorylated Parkin, and in pathways supporting mitochondrial metabolism.

Parkin helps direct the cellular machinery toward mitochondria requiring attention. Changes in its activation and in related protein networks are consistent with increased engagement of mitochondrial quality-control pathways. They are valuable mechanistic findings, particularly because the researchers also measured muscle function in the same intervention. They should nevertheless be distinguished from a direct measurement of mitophagy flux, total mitochondrial turnover, or whole-body mitochondrial rejuvenation. The study did not establish a 39% gain in energy production, muscle strength, or lifespan.

This is precisely why the trial remains interesting. The molecular measurements provide biological context for the improvements seen in selected hamstring-strength measures, while the neutral primary performance endpoint gives researchers a clear target for the next generation of trials. The original research is available in Cell Reports Medicine.

The study nevertheless provided a useful human signal connecting mitochondrial-related biology with a measurable aspect of muscular function.

Older Adults

A separate randomized trial published in JAMA Network Open studied 66 adults between 65 and 90 years of age who received 1,000 mg of urolithin A daily or placebo for four months.

Investigators found improvements in selected measures of hand and leg muscle endurance, along with changes in circulating markers associated with mitochondrial metabolism and inflammation. The prespecified primary outcomes, six-minute walking distance and maximal ATP production in hand muscle, did not show statistically significant differences between treatment and placebo groups.

This study remains relevant because resistance to muscular fatigue may influence everyday physical activity and the ability to sustain exercise. Determining whether such improvements eventually translate into better mobility, reduced frailty, or preserved independence will require larger and longer studies.

Newer Research on Exercise Recovery

A randomized trial published in Sports Medicine in August 2025 investigated urolithin A in 42 highly trained male distance runners. Participants received 1,000 mg daily or placebo for four weeks while completing an intensive training program that included altitude exposure.

The investigators examined aerobic capacity, running economy, performance, exercise recovery, and muscle tissue responses. The inclusion of muscle biopsies allowed researchers to evaluate changes in protein pathways associated with mitochondrial function and inflammation.

Participants receiving urolithin A demonstrated lower ratings of perceived exertion and reduced creatine kinase responses, a commonly used indirect marker of exercise-related muscle damage. Muscle protein analysis also revealed changes in pathways associated with mitochondria and inflammation.

The treatment did not produce a statistically significant improvement in 3,000-meter running performance, nor was there a significant between-group difference in maximal aerobic capacity. Direct measurements of mitochondrial respiration in muscle fibers were also unchanged.

The recovery findings are clinically interesting because the physiological demands of regular exercise create ongoing requirements for cellular adaptation and repair. Recovery is influenced by nutrition, sleep, training load, inflammation, and mitochondrial function. A compound capable of influencing some of these pathways warrants further investigation in older recreational exercisers and individuals undergoing progressive strength training.

These findings do not establish that urolithin A improves athletic performance or prevents exercise-related muscle injury. They provide a rationale for studying recovery-related outcomes in additional populations.

Urolithin A and Immune Aging

One of the more consequential developments in urolithin A research appeared in Nature Aging in October 2025. The MitoImmune randomized, double-blind, placebo-controlled trial enrolled 50 healthy adults between 45 and 70 years of age. Participants received 1,000 mg of urolithin A daily or placebo for four weeks.

The researchers were interested in the relationship between mitochondrial metabolism and age-associated changes in immune-cell populations. T lymphocytes, which help coordinate adaptive immune responses, depend on changes in cellular metabolism as they become activated, differentiate, and develop immunological memory.

The trial identified an increase in circulating naive-like CD8-positive T cells that were less terminally exhausted, along with increased fatty-acid oxidation capacity in CD8-positive cells. Fatty-acid oxidation allows cells to use fats as a fuel source and is one component of metabolic flexibility.

Researchers also observed changes associated with mitochondrial biogenesis, natural killer cells, monocyte populations, and selected functional responses of immune cells. Monocytes are immune cells involved in detecting and responding to pathogens, while natural killer cells participate in innate immune surveillance.

These observations suggest that the metabolic state of immune cells may be responsive to a nutritional intervention directed at mitochondrial quality-control pathways. That is meaningful because immune aging involves changes in cellular metabolism, inflammatory signaling, and the ability to maintain appropriately functioning immune populations.

The trial was designed to evaluate cellular and metabolic outcomes rather than infection rates, vaccine responses, cancer incidence, or long-term clinical health. Further research will determine whether the observed changes in immune-cell biology are associated with measurable improvements in immune resilience.

For preventive longevity medicine, this line of investigation is particularly relevant to the emerging field of immunometabolism, which examines how cellular energy pathways influence immune activity and inflammatory regulation.

Emerging Cardiovascular Research

Research published in Experimental & Molecular Medicine in July 2026 examined urolithin A in experimental models of heart failure with preserved ejection fraction, commonly abbreviated HFpEF.

In HFpEF, the heart generally maintains a relatively preserved percentage of blood ejected with each contraction, but abnormalities in relaxation, filling, and the interaction between cardiac and systemic physiology can produce significant symptoms. Obesity, hypertension, insulin resistance, inflammation, and metabolic dysfunction are important contributors to this condition.

The investigators used an experimental mouse model and complementary cellular techniques to study whether urolithin A could influence mitochondrial function and structural changes within cardiac tissue.

Urolithin A treatment was associated with improved measures of diastolic function, reduced cardiac hypertrophy and fibrosis, and restoration of aspects of mitochondrial structure and metabolism. The investigators identified changes involving AMPK and mTOR signaling, two important regulatory pathways that help cells coordinate energy availability, growth, and recycling activity.

AMPK is activated in response to changes in cellular energy status, while mTOR participates in growth and nutrient-sensing pathways. Their interaction influences autophagy and mitochondrial quality control. In this experimental study, urolithin A promoted signaling associated with the initiation of autophagy and restoration of impaired mitophagy.

The research also identified changes in the gut microbiome and circulating ceramides. Ceramides are lipid signaling molecules involved in membrane structure and cellular regulation, but excessive accumulation of certain ceramide species has been associated with metabolic stress and cardiometabolic disease.

Complementary experiments involving human stem-cell-derived cardiomyocytes identified changes in fibrosis-related cellular programming. These experiments add mechanistic relevance, although they do not establish clinical efficacy in people with heart failure.

The broader significance is the possibility that mitochondrial quality control may interact with cardiac remodeling, lipid metabolism, and inflammatory signaling. It is an intriguing direction for preventive cardiology research, particularly because cardiac and metabolic aging involve more than cholesterol levels or isolated measurements of heart function.

Urolithin A has not been demonstrated to prevent or treat HFpEF in human clinical trials. The experimental findings provide a foundation for asking whether mitochondrial-targeted nutritional interventions can eventually influence measurable cardiovascular outcomes.

Brain Circulation and Mitochondrial Health

Research involving mitochondrial biology has also extended into cerebral circulation. An October 2026 randomized human trial in adults with obesity examined the effects of urolithin A on vascular and cerebral hemodynamic measurements.

The study reported a significant cerebral hemodynamic response, while the primary endothelial outcome was not significantly improved. The results did not establish a cognitive benefit.

Vascular regulation, mitochondrial metabolism, and inflammatory signaling interact in brain health, making this an important area for continued investigation. We examine the trial design, findings, and clinical interpretation in a separate HormoneSynergy® article, Urolithin A, Brain Blood Flow, and Mitochondrial Health.

What Does It Mean That Mitopure Has 25 Studies?

Timeline, the company associated with the proprietary urolithin A ingredient Mitopure®, has described a clinical research program that includes 25 human studies. The investment in human research is noteworthy in a supplement category where many products enter the market with comparatively little direct clinical investigation.

The number requires some context. Clinical research programs include studies that differ in purpose, design, population, duration, and stage of completion. Early studies may investigate absorption, metabolism, safety, or molecular changes, while later trials examine functional or clinical outcomes. Registered studies may also be underway without having reported their results.

A July 2026 systematic review and meta-analysis identified five randomized controlled trials involving 236 participants that met its specific eligibility criteria for muscle-related outcomes. This does not mean that the broader urolithin A research program contains only five studies. It reflects the narrower question addressed by that review.

The distinction is important when interpreting the evidence. A portfolio of studies can demonstrate substantial research activity, while systematic reviews help determine how consistently particular outcomes have been reproduced in comparable clinical trials.

Another registered research initiative, CLARITY, is designed to investigate cognitive and related outcomes in approximately 650 participants. Such research may help determine whether mitochondrial-related interventions have measurable effects beyond the muscular and cellular outcomes investigated in earlier trials. Published efficacy results are needed before drawing conclusions about cognitive improvement.

ATLAS 2: A Larger Test of Muscle Outcomes

The registered ATLAS 2 study (NCT07231783) is designed to enroll approximately 120 adults ages 40 to 65 in a six-month, randomized, double-blind, placebo-controlled trial. It compares 500 mg and 1,000 mg of Mitopure® daily with placebo and places isokinetic knee-flexion strength at the center of its efficacy assessment. Its longer duration and more explicitly defined strength endpoint should help address questions raised by the 2022 trial. At the time of this update, efficacy results had not been published. View trial registration.

Industry sponsorship is common in early clinical development of proprietary nutritional ingredients. It provides resources for standardized manufacturing and controlled human trials, although independent replication and transparent reporting of prespecified outcomes remain valuable as the evidence grows.

What the 2026 Systematic Review Tells Us

The July 2026 systematic review examined randomized trials assessing urolithin A supplementation and muscle-related outcomes. Five studies involving 236 participants satisfied the investigators' eligibility criteria.

Differences in participant characteristics, assessment methods, interventions, and reported outcomes limited the ability to combine results statistically. The six-minute walk test was the principal outcome that could be pooled. The estimated difference favored urolithin A by approximately 17 meters, but the confidence interval included no effect, and the result was not statistically significant. The certainty of this evidence was rated low.

Other findings involving strength, endurance, aerobic capacity, and mitochondrial biomarkers could not be reliably combined because the measurements were too heterogeneous.

The review provides a useful perspective on the current stage of clinical development. Individual studies have produced favorable findings, particularly for selected muscular and metabolic outcomes, but larger investigations with consistent functional endpoints will be necessary to establish the size and reproducibility of clinical benefits.

The immune-aging, cardiovascular, and cerebral circulation investigations also reflect questions beyond the muscle-specific scope of this review. Those findings should be evaluated according to their own designs and outcomes.

Urolithin A, Exercise, and Creatine

Patients interested in preserving muscle function often ask whether urolithin A should be considered alongside creatine or other nutritional strategies used to support physical performance.

These compounds influence different aspects of cellular physiology. Creatine supports the phosphocreatine system, which helps regenerate ATP during periods of high energy demand. Urolithin A is being investigated primarily for its relationship with mitochondrial quality control and related metabolic processes.

Creatine has a substantially larger clinical literature for strength and exercise performance, especially when combined with resistance training. Urolithin A remains at an earlier stage of clinical development, although its emerging effects on mitochondrial and immune pathways raise different research questions.

We do not currently have adequate head-to-head trials establishing whether adding urolithin A to creatine produces greater improvements in strength, endurance, recovery, or long-term physical function than either intervention alone.

A comprehensive program for preserving muscle with age continues to include progressive resistance training, sufficient dietary protein, aerobic activity, adequate recovery, and management of underlying metabolic or hormonal concerns. Urolithin A may have a complementary role within such a program, particularly if future studies confirm meaningful effects on recovery or muscular resilience.

Can Urolithin A Help With Weight-Loss Resistance?

Mitochondria participate in energy expenditure, substrate oxidation, nutrient sensing, and metabolic adaptation. Their function is relevant to obesity, insulin resistance, and the metabolic changes that occur during weight loss.

These relationships have prompted interest in whether improving mitochondrial quality control could influence weight-management outcomes. Urolithin A has demonstrated effects on mitochondrial-related pathways in human research, and experimental work offers additional reasons to investigate its metabolic applications.

We do not yet have convincing human clinical evidence that urolithin A produces meaningful fat loss, resolves weight-loss plateaus, or improves outcomes during GLP-1 treatment. It has also not been established as an intervention that prevents medication-associated losses of lean mass.

For patients undergoing weight reduction, preserving muscle and physical function remains particularly important. Adequate protein, resistance training, nutritional sufficiency, and objective body-composition assessment provide a practical foundation. Research involving urolithin A may eventually identify a useful adjunctive role, but that application remains to be demonstrated.

What Dosage Has Been Studied?

Human trials have commonly investigated urolithin A at daily doses of 500 mg or 1,000 mg, with several of the more recent mechanistic studies using 1,000 mg.

These doses describe the interventions used in clinical research rather than an established treatment recommendation for aging or chronic disease prevention. The available studies have not defined an optimal lifelong dose, nor have they demonstrated that higher doses necessarily produce better clinical outcomes.

Mitopure is a standardized proprietary form of urolithin A. When evaluating products, the amount of urolithin A, formulation, identity and purity testing, manufacturing quality, and availability of supporting documentation are important considerations. Published findings involving a defined ingredient and dose should not automatically be generalized to unrelated formulations.

Safety and Clinical Considerations

Short-term human studies have generally reported favorable tolerability at the doses investigated. The published randomized trials have not established a consistent pattern of serious treatment-related adverse effects.

Most investigations have lasted weeks to months and involved relatively limited populations. Longer-term safety, uncommon adverse effects, medication interactions, and use in patients with significant chronic illnesses require further evaluation.

Individual assessment is appropriate during pregnancy or breastfeeding, active cancer treatment, complex medical management, or when patients are taking multiple medications. The potential metabolic and immunological effects of urolithin A are also reasons to consider the individual's overall health circumstances when evaluating supplementation.

The HormoneSynergy® Perspective

At HormoneSynergy®, we are particularly interested in interventions that may help preserve the physiological capacities associated with healthy aging. Skeletal muscle, mitochondrial function, metabolic flexibility, cardiovascular health, and appropriate immune regulation are closely interconnected, and research increasingly reflects those relationships.

Urolithin A is a meaningful example of how nutritional science can develop from basic mitochondrial biology into human investigations with measurable cellular and functional outcomes. The evidence now includes randomized studies involving muscle strength, endurance, exercise recovery, immune-cell metabolism, and vascular physiology, along with experimental research exploring cardiac remodeling.

The immune-aging findings are especially interesting to the developing understanding of immunometabolism. They suggest that the metabolic organization of immune cells may respond to interventions influencing mitochondrial quality control. Whether these changes lead to improved clinical resilience remains an important question, but the biological observations are substantial enough to justify continued investigation.

The cardiovascular and cerebral vascular findings provide additional reasons to follow this research carefully. They also reinforce the importance of studying mitochondrial biology in relation to organ function rather than evaluating isolated molecular markers without their physiological context.

Our clinical approach remains centered on identifying measurable health concerns and addressing them through comprehensive care. Progressive exercise, appropriate nutrition, sleep, cardiovascular risk assessment, and management of metabolic dysfunction remain essential. We also recognize that emerging nutritional interventions may eventually expand the options available for maintaining function and resilience with age.

When muscle preservation is an important clinical goal, assessments such as Hologic DEXA body composition and SECA bioelectrical impedance analysis can help characterize changes in lean tissue and related body-composition measures. Strength testing, exercise tolerance, nutritional status, and the patient's functional goals provide additional context. These assessments help evaluate an overall program, although they cannot independently establish that any changes were caused by a particular supplement.

Urolithin A deserves continued attention as larger clinical trials become available. Its developing evidence base offers a scientifically grounded reason to investigate mitochondrial quality control as one component of preventive longevity medicine.

Related HormoneSynergy® Resources

• Urolithin A, Brain Blood Flow, and Mitochondrial Health
• Preventive Cardiology and Longevity Medicine
• DEXA Bone Density, Body Composition, and Visceral Fat Analysis
• The HormoneSynergy® Longevity Medicine Philosophy
• Longevity Medicine Resource Library

Selected Research References

1. Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019.
2. Singh A, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. 2022.
3. Liu S, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults. JAMA Network Open. 2022.
4. Denk D, et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature Aging. 2025. Read study.
5. Whitfield J, et al. Evaluating the impact of urolithin A supplementation on running performance, recovery, and mitochondrial biomarkers in highly trained male distance runners. Sports Medicine. 2025. Read study.
6. Dao T, et al. Effects of urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. Frontiers in Nutrition. 2026.
7. Song H, et al. Urolithin A activates mitophagy via the AMPK–mTOR axis and modulates the gut–ceramide axis to ameliorate cardiac remodeling in HFpEF. Experimental & Molecular Medicine. 2026. Read study.
8. da Costa Pinaffi-Langley AC, et al. Urolithin A and endothelial and cerebrovascular function in middle-aged adults with obesity: A randomized clinical trial. JAMA Network Open. 2026. Read study.
9. ClinicalTrials.gov. ATLAS 2 study, NCT07231783. View trial registration.
10. ClinicalTrials.gov. CLARITY study, NCT07060898. View clinical trial registration.

Frequently Asked Questions

Does urolithin A improve mitochondrial health?

Human trials have demonstrated changes in selected mitochondrial-related proteins, metabolites, immune-cell metabolic responses, and functional measurements. These findings support biological activity, although clinical outcomes differ across studies and populations.

Does Mitopure have 25 clinical studies?

Timeline has described a research program involving 25 human studies. That total includes investigations with different objectives and stages of completion. It should not be interpreted as 25 published randomized trials demonstrating clinical effectiveness.

Did Mitopure® renew 39% of mitochondria?

No study measured literal replacement of 39% of mitochondria throughout the body. Timeline's figure summarizes a change in mitophagy-related biological markers observed in the 2022 four-month trial. Muscle-biopsy protein measurements support activity in mitochondrial quality-control pathways, but they are not the same as a direct count of renewed mitochondria.

Can urolithin A improve muscle strength?

Selected measurements of muscle strength and endurance have improved in randomized trials, particularly in middle-aged and older adults. The findings are encouraging, although some prespecified primary outcomes have not been statistically significant.

Can urolithin A support immune health?

A randomized trial published in Nature Aging found changes in immune-cell populations, mitochondrial metabolism, and selected cellular functions after four weeks of supplementation. Further studies are needed to determine whether these effects improve clinical immune outcomes.

Does urolithin A improve cardiovascular health?

Experimental research has identified effects on mitochondrial quality control, cardiac remodeling, and lipid-related metabolic pathways. Clinical cardiovascular benefits have not yet been established in human trials.

Is urolithin A better than creatine?

The two compounds act through different mechanisms, and adequate head-to-head clinical trials are lacking. Creatine has a larger evidence base for muscular strength and exercise performance, while urolithin A is being investigated for mitochondrial quality control and related cellular functions.

What is the difference between 500 mg and 1,000 mg of urolithin A?

Both doses have been used in human research. Several recent mechanistic trials have used 1,000 mg daily. The available evidence does not yet establish one dose as optimal for all people or for lifelong supplementation.